Another FDA-approved drug for the treatment of recurrent gliomas is bevacizumab, which is an anti-angiogenic monoclonal antibody that works by attaching to vascular endothelial growth factor (VEGF), thereby inhibiting its ability to bind to receptors on the surface of endothelial cells. Here, VEGFA is linked to glioma.